Skip to main content
PMC home page
Journal of Psychiatry & Neuroscience : JPN logoLink to Journal of Psychiatry & Neuroscience : JPN
. 1998 Mar;23(2):95–108.

Nicotine: abused substance and therapeutic agent.

J Le Houezec 1
PMCID: PMC1188908  PMID: 9549250

Abstract

Tobacco dependence is a complex phenomenon that is not fully understood. Nicotine is the main alkaloid in tobacco and the addictive compound of tobacco. It can improve both mood and cognitive functioning; these positive effects are strong reinforcements for smokers and contribute to their addiction. Opposite results also have been reported, however, and the effects of nicotine remain controversial. Recent epidemiological and empirical studies have indicated that smoking or nicotine or both may have protective effects against certain diseases. These findings have suggested that nicotine may be used as a therapeutic agent. However, because a variety of nicotinic cholinergic receptors are present in the brain, new agonist compounds may prove to be more effective than nicotine for therapeutic purposes. Studies are reviewed and the suggestion made that nicotine may prove useful as a tool to help us understand normal and pathological brain functioning.

Full text

PDF
96

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adler L. E., Hoffer L. D., Wiser A., Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry. 1993 Dec;150(12):1856–1861. doi: 10.1176/ajp.150.12.1856. [DOI] [PubMed] [Google Scholar]
  2. Albanese M. J., Khantzian E. J., Murphy S. L., Green A. I. Decreased substance use in chronically psychotic patients treated with clozapine. Am J Psychiatry. 1994 May;151(5):780–781. doi: 10.1176/ajp.151.5.780b. [DOI] [PubMed] [Google Scholar]
  3. Anfang M. K., Pope H. G., Jr Treatment of neuroleptic-induced akathisia with nicotine patches. Psychopharmacology (Berl) 1997 Nov;134(2):153–156. doi: 10.1007/s002130050436. [DOI] [PubMed] [Google Scholar]
  4. Balfour D. J., Fagerström K. O. Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol Ther. 1996;72(1):51–81. doi: 10.1016/s0163-7258(96)00099-x. [DOI] [PubMed] [Google Scholar]
  5. Baron J. A. Cigarette smoking and Parkinson's disease. Neurology. 1986 Nov;36(11):1490–1496. doi: 10.1212/wnl.36.11.1490. [DOI] [PubMed] [Google Scholar]
  6. Bencherif M., Lovette M. E., Fowler K. W., Arrington S., Reeves L., Caldwell W. S., Lippiello P. M. RJR-2403: a nicotinic agonist with CNS selectivity I. In vitro characterization. J Pharmacol Exp Ther. 1996 Dec;279(3):1413–1421. [PubMed] [Google Scholar]
  7. Benowitz N. L. Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addition. N Engl J Med. 1988 Nov 17;319(20):1318–1330. doi: 10.1056/NEJM198811173192005. [DOI] [PubMed] [Google Scholar]
  8. Benowitz N. L., Jacob P., 3rd Daily intake of nicotine during cigarette smoking. Clin Pharmacol Ther. 1984 Apr;35(4):499–504. doi: 10.1038/clpt.1984.67. [DOI] [PubMed] [Google Scholar]
  9. Benowitz N. L., Jacob P., 3rd, Jones R. T., Rosenberg J. Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp Ther. 1982 May;221(2):368–372. [PubMed] [Google Scholar]
  10. Benowitz N. L., Kuyt F., Jacob P., 3rd Circadian blood nicotine concentrations during cigarette smoking. Clin Pharmacol Ther. 1982 Dec;32(6):758–764. doi: 10.1038/clpt.1982.233. [DOI] [PubMed] [Google Scholar]
  11. Benowitz N. L. Pharmacokinetic considerations in understanding nicotine dependence. Ciba Found Symp. 1990;152:186–209. doi: 10.1002/9780470513965.ch11. [DOI] [PubMed] [Google Scholar]
  12. Benowitz N. L. Pharmacology of nicotine: addiction and therapeutics. Annu Rev Pharmacol Toxicol. 1996;36:597–613. doi: 10.1146/annurev.pa.36.040196.003121. [DOI] [PubMed] [Google Scholar]
  13. Benwell M. E., Balfour D. J. Central nicotine binding sites: a study of post-mortem stability. Neuropharmacology. 1985 Nov;24(11):1135–1137. doi: 10.1016/0028-3908(85)90205-9. [DOI] [PubMed] [Google Scholar]
  14. Berlin I., Said S., Spreux-Varoquaux O., Olivares R., Launay J. M., Puech A. J. Monoamine oxidase A and B activities in heavy smokers. Biol Psychiatry. 1995 Dec 1;38(11):756–761. doi: 10.1016/0006-3223(95)00084-4. [DOI] [PubMed] [Google Scholar]
  15. Berlin I., Saïd S., Spreux-Varoquaux O., Launay J. M., Olivares R., Millet V., Lecrubier Y., Puech A. J. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther. 1995 Oct;58(4):444–452. doi: 10.1016/0009-9236(95)90058-6. [DOI] [PubMed] [Google Scholar]
  16. Breslau N., Kilbey M. M., Andreski P. Nicotine withdrawal symptoms and psychiatric disorders: findings from an epidemiologic study of young adults. Am J Psychiatry. 1992 Apr;149(4):464–469. doi: 10.1176/ajp.149.4.464. [DOI] [PubMed] [Google Scholar]
  17. Breslau N. Psychiatric comorbidity of smoking and nicotine dependence. Behav Genet. 1995 Mar;25(2):95–101. doi: 10.1007/BF02196920. [DOI] [PubMed] [Google Scholar]
  18. Buccafusco J. J., Jackson W. J., Terry A. V., Jr, Marsh K. C., Decker M. W., Arneric S. P. Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement. Psychopharmacology (Berl) 1995 Aug;120(3):256–266. doi: 10.1007/BF02311172. [DOI] [PubMed] [Google Scholar]
  19. Cabib S., Puglisi-Allegra S. Stress, depression and the mesolimbic dopamine system. Psychopharmacology (Berl) 1996 Dec;128(4):331–342. doi: 10.1007/s002130050142. [DOI] [PubMed] [Google Scholar]
  20. Carton S., Jouvent R., Widlöcher D. Nicotine dependence and motives for smoking in depression. J Subst Abuse. 1994;6(1):67–76. doi: 10.1016/s0899-3289(94)90091-4. [DOI] [PubMed] [Google Scholar]
  21. Clarke P. B., Fu D. S., Jakubovic A., Fibiger H. C. Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats. J Pharmacol Exp Ther. 1988 Aug;246(2):701–708. [PubMed] [Google Scholar]
  22. Clarke P. B. Nicotine dependence--mechanisms and therapeutic strategies. Biochem Soc Symp. 1993;59:83–95. [PubMed] [Google Scholar]
  23. Clarke P. B. Nicotinic receptors in mammalian brain: localization and relation to cholinergic innervation. Prog Brain Res. 1993;98:77–83. doi: 10.1016/s0079-6123(08)62383-3. [DOI] [PubMed] [Google Scholar]
  24. Clemens P., Baron J. A., Coffey D., Reeves A. The short-term effect of nicotine chewing gum in patients with Parkinson's disease. Psychopharmacology (Berl) 1995 Jan;117(2):253–256. doi: 10.1007/BF02245195. [DOI] [PubMed] [Google Scholar]
  25. Cloninger C. R. A systematic method for clinical description and classification of personality variants. A proposal. Arch Gen Psychiatry. 1987 Jun;44(6):573–588. doi: 10.1001/archpsyc.1987.01800180093014. [DOI] [PubMed] [Google Scholar]
  26. Coggan J. S., Paysan J., Conroy W. G., Berg D. K. Direct recording of nicotinic responses in presynaptic nerve terminals. J Neurosci. 1997 Aug 1;17(15):5798–5806. doi: 10.1523/JNEUROSCI.17-15-05798.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Corrigall W. A., Franklin K. B., Coen K. M., Clarke P. B. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl) 1992;107(2-3):285–289. doi: 10.1007/BF02245149. [DOI] [PubMed] [Google Scholar]
  28. Couturier S., Bertrand D., Matter J. M., Hernandez M. C., Bertrand S., Millar N., Valera S., Barkas T., Ballivet M. A neuronal nicotinic acetylcholine receptor subunit (alpha 7) is developmentally regulated and forms a homo-oligomeric channel blocked by alpha-BTX. Neuron. 1990 Dec;5(6):847–856. doi: 10.1016/0896-6273(90)90344-f. [DOI] [PubMed] [Google Scholar]
  29. Covey L. S., Glassman A. H., Stetner F. Depression and depressive symptoms in smoking cessation. Compr Psychiatry. 1990 Jul-Aug;31(4):350–354. doi: 10.1016/0010-440x(90)90042-q. [DOI] [PubMed] [Google Scholar]
  30. Covey L. S., Glassman A. H., Stetner F. Major depression following smoking cessation. Am J Psychiatry. 1997 Feb;154(2):263–265. doi: 10.1176/ajp.154.2.263. [DOI] [PubMed] [Google Scholar]
  31. Dale L. C., Hurt R. D., Offord K. P., Lawson G. M., Croghan I. T., Schroeder D. R. High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. JAMA. 1995 Nov 1;274(17):1353–1358. [PubMed] [Google Scholar]
  32. Damaj M. I., Creasy K. R., Welch S. P., Rosecrans J. A., Aceto M. D., Martin B. R. Comparative pharmacology of nicotine and ABT-418, a new nicotinic agonist. Psychopharmacology (Berl) 1995 Aug;120(4):483–490. doi: 10.1007/BF02245822. [DOI] [PubMed] [Google Scholar]
  33. Dawe S., Gerada C., Russell M. A., Gray J. A. Nicotine intake in smokers increases following a single dose of haloperidol. Psychopharmacology (Berl) 1995 Jan;117(1):110–115. doi: 10.1007/BF02245105. [DOI] [PubMed] [Google Scholar]
  34. Decker M. W., Bannon A. W., Curzon P., Gunther K. L., Brioni J. D., Holladay M. W., Lin N. H., Li Y., Daanen J. F., Buccafusco J. J. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys. J Pharmacol Exp Ther. 1997 Oct;283(1):247–258. [PubMed] [Google Scholar]
  35. Decker M. W., Brioni J. D., Sullivan J. P., Buckley M. J., Radek R. J., Raszkiewicz J. L., Kang C. H., Kim D. J., Giardina W. J., Wasicak J. T. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization. J Pharmacol Exp Ther. 1994 Jul;270(1):319–328. [PubMed] [Google Scholar]
  36. Deneris E. S., Connolly J., Rogers S. W., Duvoisin R. Pharmacological and functional diversity of neuronal nicotinic acetylcholine receptors. Trends Pharmacol Sci. 1991 Jan;12(1):34–40. doi: 10.1016/0165-6147(91)90486-c. [DOI] [PubMed] [Google Scholar]
  37. Emerich D. F., Norman A. B., Sanberg P. R. Nicotine potentiates the behavioral effects of haloperidol. Psychopharmacol Bull. 1991;27(3):385–390. [PubMed] [Google Scholar]
  38. Emerich D. F., Zanol M. D., Norman A. B., McConville B. J., Sanberg P. R. Nicotine potentiates haloperidol-induced catalepsy and locomotor hypoactivity. Pharmacol Biochem Behav. 1991 Apr;38(4):875–880. doi: 10.1016/0091-3057(91)90256-2. [DOI] [PubMed] [Google Scholar]
  39. Fagerström K. O., Pomerleau O., Giordani B., Stelson F. Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology (Berl) 1994 Sep;116(1):117–119. doi: 10.1007/BF02244882. [DOI] [PubMed] [Google Scholar]
  40. Fagerström K. O., Schneider N. G., Lunell E. Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms. Psychopharmacology (Berl) 1993;111(3):271–277. doi: 10.1007/BF02244941. [DOI] [PubMed] [Google Scholar]
  41. Fergusson D. M., Lynskey M. T., Horwood L. J. Comorbidity between depressive disorders and nicotine dependence in a cohort of 16-year-olds. Arch Gen Psychiatry. 1996 Nov;53(11):1043–1047. doi: 10.1001/archpsyc.1996.01830110081010. [DOI] [PubMed] [Google Scholar]
  42. Fiore M. C., Smith S. S., Jorenby D. E., Baker T. B. The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA. 1994 Jun 22;271(24):1940–1947. [PubMed] [Google Scholar]
  43. Foulds J., Stapleton J., Swettenham J., Bell N., McSorley K., Russell M. A. Cognitive performance effects of subcutaneous nicotine in smokers and never-smokers. Psychopharmacology (Berl) 1996 Sep;127(1):31–38. doi: 10.1007/BF02805972. [DOI] [PubMed] [Google Scholar]
  44. Fowler J. S., Volkow N. D., Wang G. J., Pappas N., Logan J., MacGregor R., Alexoff D., Shea C., Schlyer D., Wolf A. P. Inhibition of monoamine oxidase B in the brains of smokers. Nature. 1996 Feb 22;379(6567):733–736. doi: 10.1038/379733a0. [DOI] [PubMed] [Google Scholar]
  45. Freedman R., Coon H., Myles-Worsley M., Orr-Urtreger A., Olincy A., Davis A., Polymeropoulos M., Holik J., Hopkins J., Hoff M. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):587–592. doi: 10.1073/pnas.94.2.587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Fuxe K., Janson A. M., Jansson A., Andersson K., Eneroth P., Agnati L. F. Chronic nicotine treatment increases dopamine levels and reduces dopamine utilization in substantia nigra and in surviving forebrain dopamine nerve terminal systems after a partial di-mesencephalic hemitransection. Naunyn Schmiedebergs Arch Pharmacol. 1990 Mar;341(3):171–181. doi: 10.1007/BF00169727. [DOI] [PubMed] [Google Scholar]
  47. Gilbert D. G., Estes S. L., Welser R. Does noise stress modulate effects of smoking/nicotine? Mood, vigilance, and EEG responses. Psychopharmacology (Berl) 1997 Feb;129(4):382–389. doi: 10.1007/s002130050204. [DOI] [PubMed] [Google Scholar]
  48. Glassman A. H. Cigarette smoking: implications for psychiatric illness. Am J Psychiatry. 1993 Apr;150(4):546–553. doi: 10.1176/ajp.150.4.546. [DOI] [PubMed] [Google Scholar]
  49. Goff D. C., Henderson D. C., Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry. 1992 Sep;149(9):1189–1194. doi: 10.1176/ajp.149.9.1189. [DOI] [PubMed] [Google Scholar]
  50. Gopalaswamy A. K., Morgan R. Smoking in chronic schizophrenia. Br J Psychiatry. 1986 Oct;149:523–523. [PubMed] [Google Scholar]
  51. Halliday R., Naylor H., Brandeis D., Callaway E., Yano L., Herzig K. The effect of D-amphetamine, clonidine, and yohimbine on human information processing. Psychophysiology. 1994 Jul;31(4):331–337. doi: 10.1111/j.1469-8986.1994.tb02441.x. [DOI] [PubMed] [Google Scholar]
  52. Henningfield J. E., Keenan R. M. Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol. 1993 Oct;61(5):743–750. doi: 10.1037//0022-006x.61.5.743. [DOI] [PubMed] [Google Scholar]
  53. Hildebrand B. E., Nomikos G. G., Bondjers C., Nisell M., Svensson T. H. Behavioral manifestations of the nicotine abstinence syndrome in the rat: peripheral versus central mechanisms. Psychopharmacology (Berl) 1997 Feb;129(4):348–356. doi: 10.1007/s002130050200. [DOI] [PubMed] [Google Scholar]
  54. Hillier V., Salib E. A case-control study of smoking and Alzheimer's disease. Int J Geriatr Psychiatry. 1997 Mar;12(3):295–300. doi: 10.1002/(sici)1099-1166(199703)12:3<295::aid-gps476>3.3.co;2-v. [DOI] [PubMed] [Google Scholar]
  55. Hughes J. R. Distinguishing withdrawal relief and direct effects of smoking. Psychopharmacology (Berl) 1991;104(3):409–410. doi: 10.1007/BF02246044. [DOI] [PubMed] [Google Scholar]
  56. Hughes J. R., Hatsukami D. K., Mitchell J. E., Dahlgren L. A. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry. 1986 Aug;143(8):993–997. doi: 10.1176/ajp.143.8.993. [DOI] [PubMed] [Google Scholar]
  57. Hughes J. R. Who are these "nonsmokers"? Am J Public Health. 1996 May;86(5):745–746. doi: 10.2105/ajph.86.5.745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Hurt R. D., Sachs D. P., Glover E. D., Offord K. P., Johnston J. A., Dale L. C., Khayrallah M. A., Schroeder D. R., Glover P. N., Sullivan C. R. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997 Oct 23;337(17):1195–1202. doi: 10.1056/NEJM199710233371703. [DOI] [PubMed] [Google Scholar]
  59. Imperato A., Mulas A., Di Chiara G. Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol. 1986 Dec 16;132(2-3):337–338. doi: 10.1016/0014-2999(86)90629-1. [DOI] [PubMed] [Google Scholar]
  60. James J. R., Nordberg A. Genetic and environmental aspects of the role of nicotinic receptors in neurodegenerative disorders: emphasis on Alzheimer's disease and Parkinson's disease. Behav Genet. 1995 Mar;25(2):149–159. doi: 10.1007/BF02196924. [DOI] [PubMed] [Google Scholar]
  61. Janson A. M., Fuxe K., Agnati L. F., Kitayama I., Härfstrand A., Andersson K., Goldstein M. Chronic nicotine treatment counteracts the disappearance of tyrosine-hydroxylase-immunoreactive nerve cell bodies, dendrites and terminals in the mesostriatal dopamine system of the male rat after partial hemitransection. Brain Res. 1988 Jul 12;455(2):332–345. doi: 10.1016/0006-8993(88)90092-3. [DOI] [PubMed] [Google Scholar]
  62. Janson A. M., Hedlund P. B., Fuxe K., von Euler G. Chronic nicotine treatment counteracts dopamine D2 receptor upregulation induced by a partial meso-diencephalic hemitransection in the rat. Brain Res. 1994 Aug 29;655(1-2):25–32. doi: 10.1016/0006-8993(94)91593-8. [DOI] [PubMed] [Google Scholar]
  63. Jones G. M., Sahakian B. J., Levy R., Warburton D. M., Gray J. A. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology (Berl) 1992;108(4):485–494. doi: 10.1007/BF02247426. [DOI] [PubMed] [Google Scholar]
  64. Jorenby D. E., Smith S. S., Fiore M. C., Hurt R. D., Offord K. P., Croghan I. T., Hays J. T., Lewis S. F., Baker T. B. Varying nicotine patch dose and type of smoking cessation counseling. JAMA. 1995 Nov 1;274(17):1347–1352. [PubMed] [Google Scholar]
  65. Kendler K. S., Neale M. C., MacLean C. J., Heath A. C., Eaves L. J., Kessler R. C. Smoking and major depression. A causal analysis. Arch Gen Psychiatry. 1993 Jan;50(1):36–43. doi: 10.1001/archpsyc.1993.01820130038007. [DOI] [PubMed] [Google Scholar]
  66. Kihara T., Shimohama S., Sawada H., Kimura J., Kume T., Kochiyama H., Maeda T., Akaike A. Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. Ann Neurol. 1997 Aug;42(2):159–163. doi: 10.1002/ana.410420205. [DOI] [PubMed] [Google Scholar]
  67. Ksir C., Benson D. M. Enhanced behavioral response to nicotine in an animal model of Alzheimer's disease. Psychopharmacology (Berl) 1983;81(3):272–273. doi: 10.1007/BF00427277. [DOI] [PubMed] [Google Scholar]
  68. Le Houezec J., Benowitz N. L. Basic and clinical psychopharmacology of nicotine. Clin Chest Med. 1991 Dec;12(4):681–699. [PubMed] [Google Scholar]
  69. Le Houezec J., Halliday R., Benowitz N. L., Callaway E., Naylor H., Herzig K. A low dose of subcutaneous nicotine improves information processing in non-smokers. Psychopharmacology (Berl) 1994 May;114(4):628–634. doi: 10.1007/BF02244994. [DOI] [PubMed] [Google Scholar]
  70. Lee P. N. Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology. 1994;13(4):131–144. doi: 10.1159/000110372. [DOI] [PubMed] [Google Scholar]
  71. Levin E. D., Conners C. K., Sparrow E., Hinton S. C., Erhardt D., Meck W. H., Rose J. E., March J. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl) 1996 Jan;123(1):55–63. doi: 10.1007/BF02246281. [DOI] [PubMed] [Google Scholar]
  72. Levin E. D. Nicotinic systems and cognitive function. Psychopharmacology (Berl) 1992;108(4):417–431. doi: 10.1007/BF02247415. [DOI] [PubMed] [Google Scholar]
  73. Madhok T. C., Beyer H. S., Sharp B. M. Protein kinase A regulates nicotinic cholinergic receptors and subunit messenger ribonucleic acids in PC 12 cells. Endocrinology. 1994 Jan;134(1):91–96. doi: 10.1210/endo.134.1.8275974. [DOI] [PubMed] [Google Scholar]
  74. Marks M. J., Pauly J. R., Gross S. D., Deneris E. S., Hermans-Borgmeyer I., Heinemann S. F., Collins A. C. Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment. J Neurosci. 1992 Jul;12(7):2765–2784. doi: 10.1523/JNEUROSCI.12-07-02765.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Marshall J., Schnieden H. Effect of adrenaline, noradrenaline, atropine, and nicotine on some types of human tremor. J Neurol Neurosurg Psychiatry. 1966 Jun;29(3):214–218. doi: 10.1136/jnnp.29.3.214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Masterson E., O'Shea B. Smoking and malignancy in schizophrenia. Br J Psychiatry. 1984 Oct;145:429–432. doi: 10.1192/bjp.145.4.429. [DOI] [PubMed] [Google Scholar]
  77. McConville B. J., Sanberg P. R., Fogelson M. H., King J., Cirino P., Parker K. W., Norman A. B. The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette's disorder. Biol Psychiatry. 1992 Apr 15;31(8):832–840. doi: 10.1016/0006-3223(92)90315-q. [DOI] [PubMed] [Google Scholar]
  78. McEvoy J. P., Freudenreich O., Levin E. D., Rose J. E. Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology (Berl) 1995 May;119(1):124–126. doi: 10.1007/BF02246063. [DOI] [PubMed] [Google Scholar]
  79. McEvoy J., Freudenreich O., McGee M., VanderZwaag C., Levin E., Rose J. Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry. 1995 Apr 15;37(8):550–552. doi: 10.1016/0006-3223(94)00365-A. [DOI] [PubMed] [Google Scholar]
  80. Newhouse P. A., Potter A., Corwin J., Lenox R. Acute nicotinic blockade produces cognitive impairment in normal humans. Psychopharmacology (Berl) 1992;108(4):480–484. doi: 10.1007/BF02247425. [DOI] [PubMed] [Google Scholar]
  81. Newhouse P. A., Sunderland T., Tariot P. N., Blumhardt C. L., Weingartner H., Mellow A., Murphy D. L. Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology (Berl) 1988;95(2):171–175. doi: 10.1007/BF00174504. [DOI] [PubMed] [Google Scholar]
  82. O'Farrell T. J., Connors G. J., Upper D. Addictive behaviors among hospitalized psychiatric patients. Addict Behav. 1983;8(4):329–333. doi: 10.1016/0306-4603(83)90032-1. [DOI] [PubMed] [Google Scholar]
  84. Perkins K. A., Epstein L. H., Stiller R. L., Sexton J. E., Debski T. D., Jacob R. G. Behavioral performance effects of nicotine in smokers and nonsmokers. Pharmacol Biochem Behav. 1990 Sep;37(1):11–15. doi: 10.1016/0091-3057(90)90035-g. [DOI] [PubMed] [Google Scholar]
  85. Perkins K. A., Grobe J. E., Fonte C., Goettler J., Caggiula A. R., Reynolds W. A., Stiller R. L., Scierka A., Jacob R. G. Chronic and acute tolerance to subjective, behavioral and cardiovascular effects of nicotine in humans. J Pharmacol Exp Ther. 1994 Aug;270(2):628–638. [PubMed] [Google Scholar]
  86. Pich E. M., Pagliusi S. R., Tessari M., Talabot-Ayer D., Hooft van Huijsduijnen R., Chiamulera C. Common neural substrates for the addictive properties of nicotine and cocaine. Science. 1997 Jan 3;275(5296):83–86. doi: 10.1126/science.275.5296.83. [DOI] [PubMed] [Google Scholar]
  87. Pickworth W. B., Fant R. V., Butschky M. F., Henningfield J. E. Effects of mecamylamine on spontaneous EEG and performance in smokers and non-smokers. Pharmacol Biochem Behav. 1997 Feb;56(2):181–187. doi: 10.1016/s0091-3057(96)00183-9. [DOI] [PubMed] [Google Scholar]
  88. Pomerleau O. F., Collins A. C., Shiffman S., Pomerleau C. S. Why some people smoke and others do not: new perspectives. J Consult Clin Psychol. 1993 Oct;61(5):723–731. doi: 10.1037//0022-006x.61.5.723. [DOI] [PubMed] [Google Scholar]
  89. Pomerleau O. F. Individual differences in sensitivity to nicotine: implications for genetic research on nicotine dependence. Behav Genet. 1995 Mar;25(2):161–177. doi: 10.1007/BF02196925. [DOI] [PubMed] [Google Scholar]
  90. Quirion R., Richard J., Wilson A. Muscarinic and nicotinic modulation of cortical acetylcholine release monitored by in vivo microdialysis in freely moving adult rats. Synapse. 1994 Jun;17(2):92–100. doi: 10.1002/syn.890170205. [DOI] [PubMed] [Google Scholar]
  91. Revell A. D. Smoking and performance--a puff-by-puff analysis. Psychopharmacology (Berl) 1988;96(4):563–565. doi: 10.1007/BF02180043. [DOI] [PubMed] [Google Scholar]
  92. Role L. W., Berg D. K. Nicotinic receptors in the development and modulation of CNS synapses. Neuron. 1996 Jun;16(6):1077–1085. doi: 10.1016/s0896-6273(00)80134-8. [DOI] [PubMed] [Google Scholar]
  93. Rose J. E., Corrigall W. A. Nicotine self-administration in animals and humans: similarities and differences. Psychopharmacology (Berl) 1997 Mar;130(1):28–40. doi: 10.1007/s002130050209. [DOI] [PubMed] [Google Scholar]
  94. Sanberg P. R., Silver A. A., Shytle R. D., Philipp M. K., Cahill D. W., Fogelson H. M., McConville B. J. Nicotine for the treatment of Tourette's syndrome. Pharmacol Ther. 1997;74(1):21–25. doi: 10.1016/s0163-7258(96)00199-4. [DOI] [PubMed] [Google Scholar]
  95. Schneider N. G., Olmstead R., Mody F. V., Doan K., Franzon M., Jarvik M. E., Steinberg C. Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. Addiction. 1995 Dec;90(12):1671–1682. doi: 10.1046/j.1360-0443.1995.901216719.x. [DOI] [PubMed] [Google Scholar]
  96. Schneider N. G., Olmstead R., Nilsson F., Mody F. V., Franzon M., Doan K. Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo-controlled trial. Addiction. 1996 Sep;91(9):1293–1306. [PubMed] [Google Scholar]
  97. Schuh K. J., Schuh L. M., Henningfield J. E., Stitzer M. L. Nicotine nasal spray and vapor inhaler: abuse liability assessment. Psychopharmacology (Berl) 1997 Apr;130(4):352–361. doi: 10.1007/s002130050250. [DOI] [PubMed] [Google Scholar]
  98. Sershen H., Balla A., Lajtha A., Vizi E. S. Characterization of nicotinic receptors involved in the release of noradrenaline from the hippocampus. Neuroscience. 1997 Mar;77(1):121–130. doi: 10.1016/s0306-4522(96)00425-3. [DOI] [PubMed] [Google Scholar]
  99. Silver A. A., Sanberg P. R. Transdermal nicotine patch and potentiation of haloperidol in Tourette's syndrome. Lancet. 1993 Jul 17;342(8864):182–182. doi: 10.1016/0140-6736(93)91392-y. [DOI] [PubMed] [Google Scholar]
  100. Sullivan J. P., Donnelly-Roberts D., Briggs C. A., Anderson D. J., Gopalakrishnan M., Xue I. C., Piattoni-Kaplan M., Molinari E., Campbell J. E., McKenna D. G. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties. J Pharmacol Exp Ther. 1997 Oct;283(1):235–246. [PubMed] [Google Scholar]
  101. Sutherland G., Russell M. A., Stapleton J., Feyerabend C., Ferno O. Nasal nicotine spray: a rapid nicotine delivery system. Psychopharmacology (Berl) 1992;108(4):512–518. doi: 10.1007/BF02247430. [DOI] [PubMed] [Google Scholar]
  102. Séguéla P., Wadiche J., Dineley-Miller K., Dani J. A., Patrick J. W. Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. J Neurosci. 1993 Feb;13(2):596–604. doi: 10.1523/JNEUROSCI.13-02-00596.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  103. Ward P. B., Hoffer L. D., Liebert B. J., Catts S. V., O'Donnell M., Adler L. E. Replication of a P50 auditory gating deficit in Australian patients with schizophrenia. Psychiatry Res. 1996 Sep 27;64(2):121–135. doi: 10.1016/0165-1781(96)02876-4. [DOI] [PubMed] [Google Scholar]
  104. Wesnes K., Warburton D. M. Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology (Berl) 1984;82(3):147–150. doi: 10.1007/BF00427761. [DOI] [PubMed] [Google Scholar]
  105. Whitehouse P. J., Martino A. M., Antuono P. G., Lowenstein P. R., Coyle J. T., Price D. L., Kellar K. J. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res. 1986 Apr 16;371(1):146–151. doi: 10.1016/0006-8993(86)90819-x. [DOI] [PubMed] [Google Scholar]
  106. Whiting P. J., Lindstrom J. M. Characterization of bovine and human neuronal nicotinic acetylcholine receptors using monoclonal antibodies. J Neurosci. 1988 Sep;8(9):3395–3404. doi: 10.1523/JNEUROSCI.08-09-03395.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  107. Willner P. Dopamine and depression: a review of recent evidence. III. The effects of antidepressant treatments. Brain Res. 1983 Dec;287(3):237–246. doi: 10.1016/0165-0173(83)90007-3. [DOI] [PubMed] [Google Scholar]
  108. Wilson A. L., Langley L. K., Monley J., Bauer T., Rottunda S., McFalls E., Kovera C., McCarten J. R. Nicotine patches in Alzheimer's disease: pilot study on learning, memory, and safety. Pharmacol Biochem Behav. 1995 Jun-Jul;51(2-3):509–514. doi: 10.1016/0091-3057(95)00043-v. [DOI] [PubMed] [Google Scholar]
  109. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci. 1997 Feb;20(2):92–98. doi: 10.1016/s0166-2236(96)10073-4. [DOI] [PubMed] [Google Scholar]
  110. Wonnacott S. The paradox of nicotinic acetylcholine receptor upregulation by nicotine. Trends Pharmacol Sci. 1990 Jun;11(6):216–219. doi: 10.1016/0165-6147(90)90242-z. [DOI] [PubMed] [Google Scholar]
  111. Zuckerman M., Eysenck S., Eysenck H. J. Sensation seeking in England and America: cross-cultural, age, and sex comparisons. J Consult Clin Psychol. 1978 Feb;46(1):139–149. doi: 10.1037//0022-006x.46.1.139. [DOI] [PubMed] [Google Scholar]
  112. de Wit H., Bodker B., Ambre J. Rate of increase of plasma drug level influences subjective response in humans. Psychopharmacology (Berl) 1992;107(2-3):352–358. doi: 10.1007/BF02245161. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Psychiatry and Neuroscience are provided here courtesy of Canadian Medical Association

RESOURCES